EVALUATION OF ANTI-ANXIETY EFFECT OF NIFEDIPINE COMPARED TO DIAZEPAM IN SWISS ALBINO MICE USING BEHAVIOURAL MODELS
Objective: The present study was undertaken to evaluate the acute and chronic anxiolytic effects of nifedipine in comparison to diazepam using in Swiss Albino mice using two behavioral models.
Methods: 30 Swiss albino mice were divided into 5 groups with 6 mice in each group. The study was conducted in two phases to evaluate acute and chronic effects. The groups consisted of diazepam (1 mg/kg), 3 doses of nifedipine (2.6 mg/kg, 5.2 mg/kg and 10.4 mg/kg) and vehicle control. The Elevated Plus Maze (EPM) and Light and Dark box were used to evaluate the anti-anxiety effects. The number of entries and time spent in the open arm of the elevated plus-maze and in the light area of light and dark box model were noted and compared among the 5 groups. Observations were analyzed using ANOVA and post hoc Tukey's test.
Results: Nifedipine (5.2 mg/kg and 10.4 mg/kg) significantly increased the number of entries and time spent in the open arm compared to vehicle control in the EPM test (p<0.001). Similarly, in the light and dark box test, nifedipine (5.2 mg/kg and 10.4 mg/kg) increased the number of entries and time spent in the light area compared to vehicle control (p<0.05). However, the low dose of nifedipine (2.6 mg/kg) did not exhibit significant findings.
Conclusion: Two doses of nifedipine (5.2 mg/kg and 10.4 mg/kg) possess anti-anxiety effects both on acute and chronic administration in both elevated plus maze and light and dark box model.
2. Olatunji BO, Cisler JM, Tolin DF. Quality of life in anxiety disorders: a meta-analytic review. Clin Psychol Rev 2007;27:572-81.
3. Shri R. Anxiety: causes and management. Int J Behav Sci 2010;5:100-18.
4. Manavi C, Rajkumar V, Vijai L. Anxiolytic effects of Plumeria rubra var. acutifolia (Poiret) L. flower extracts in the elevated plus-maze model of anxiety in mice. Asian J Psychiat 2013;6:113–8.
5. Mahendra P, Bisht S. Anti-anxiety activity of Coriandrum sativum assessed using different experimental anxiety models. Indian J Pharmacol 2011;43:574-7.
6. Soodan S, Arya A. Understanding the pathophysiology and management of anxiety disorders. Int J Pharm Pharm Res 2015;4:251-78.
7. Catterall WA. Voltage-gated calcium channels. Cold Spring Harbor Perspect Biol 2011;3:1-23.
8. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens 2011;13:687-9.
9. Larkin JG, Thompson GG, Scobie G, Forrest G, Drennan JE, Brodie MJ. Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. Epilepsia 1992;33:760-9.
10. El Ganouni S, Tazi A, Hakkou F. Potential serotonergic interactions with the anxiolytic-like effects of calcium channel antagonists. Pharmacol Biochem Behav 1998;60:365-9.
11. Umukoro S, Ashorobi RB, Essein EE. Anticonvulsant and anxiolytic effects of calcium channel blockers in mice. J Med Sci 2006;6:1021-4.
12. Tanwani H, Nyati P, Atal S, Churihar R. Evaluation of antianxiety, antidepressant and sedative effects of nimodipine in swiss albino mice. Int J Pharm Pharm Sci 2016;8:260-3.
13. Goodman L, Gilman A, Brunton L, Hilal Dandan R, Knollmann B. Goodman and Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.
14. Sreedharan N, Rao PG, Rau NR, Shankar PR. Antihypertensive prescribing preferences in three South Indian Hospitals: cost analysis, physicians' perspectives and emerging trends. Int J Clin Pharmacol Ther 2011;49:277.
15. Gupta R, Malhotra A, Malhotra P. Study of prescribing pattern of drugs used in the treatment of hypertension in a tertiary care teaching hospital in North India: an observational study. Int J Res Med Sci 2018;6:2380.
16. Sweetman SC. Martindale: the complete drug reference. 36th Edition. London: Pharmaceutical Press: Cardiovascular drugs; 2009.
17. Nishino T, Takeuchi T, Takechi K, Kamei C. Evaluation of anxiolytic-like effects of some short-acting benzodiazepine hypnotics in mice. J Pharmacol Sci 2008;107:349-54.
18. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007;2:322-8.
19. Veena RI, Kiranmai G, RAVI PP. Pharmacological evaluation of the antianxiety activity of Desmostachya bipinnata leaves in animal models. Int J Curr Pharm Res 2017;9:152-4.
20. Bourin M, Hascoët M. The mouse light/dark box test. Eur J Pharmacol 2003;463:55-65.
21. Moser DK. The rust of life: impact of anxiety on cardiac patients. Am J Crit Care 2007;16:361-9.
22. Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R. Brain pharmacokinetics and in vivo receptor binding of 1, 4-dihydropyridine calcium channel antagonists. Life Sci 1997;61:2083-90.
23. Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry 1999;60 Suppl 22:12-7.
24. Cortes R, Supavilai P, Karobath M, Palacios JM. Calcium antagonist binding sites in the rat brain: quantitative autoradiographic mapping using the 1, 4-dihydropyridines [3 H] PN 200-110 and [3 H] PY 108-068. J Neural Transm 1984;60:169-97.
25. Feder A, Costi S, Iacoviello B, Murrough J, Charney D. Anxiety disorders: neurobiology and neuroscience. In: B Sadock, V Sadock, P Ruiz, ed. Kaplan and sadock's comprehensive textbook of psychiatry. 10th ed. Philadelphia: Wolters Kluwer Health/lippincott Williams and Wilkins; 2017.
26. Pan Y, Cai W, Cheng Q, Dong W, An T, Yan J. Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatr Dis Treat 2015;11:1121.
This work is licensed under a Creative Commons Attribution 4.0 International License.